Src

VEGFR (Flt and KDR) inhibitor

Bosutinib (SKI-606) is an oral Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively.

EphB4 inhibitor,potent and selective

Fingolimod (FTY720), an immunosuppressant agent, usually used in the treatment of multiple sclerosis, also has anticancer actions and can act as an HDACi (Histone deacetylase inhibitors)[1].

Saracatinib (AZD0530) (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib (AZD0530) shows high selectivity over other tyrosine kinases.

Osteogenic Growth Peptide (10-14) is a truncated pentapeptide fragment of the active osteogenic growth peptide (OGP) and is a Src kinase (Src) inhibitor.

Inhibitor of Src/Syk tyrosine kinases

A Src kinase inhibitor

PP 2 (AG 1879) is a selective Src family kinase inhibitor. The IC 50 values of PP 2 for inhibiting Lck and Fyn are 0.004μM and 0.005μM, respectively.

MLR 1023 is a potent and selective allosteric activator of Lyn kinase with an EC50 of 63 nM.

Dual inhibitor of tyrosine and phosphoinositide kinases

Phosphopeptide for binding to the src SH2 domain

Src family kinases inhibitor

Phosphopeptide ligand for the src SH2 domain

Selective inhibitor of Syk kinase

A tyrosine kinase inhibitor

A selective inhibitor of lymphocyte-specific protein tyrosine kinase

Masitinib (AB1010) (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity.

Dual Src/Abl kinase inhibitor, ATP-competitive,

Lck/Src inhibitor,potent and selective

Negative control for the Src kinase inhibitor PP 2

DCC-2036 (Rebastinib) (DCC-2036) is an orally active, non-ATP-competitiveBcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. DCC-2036 (Rebastinib) also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.